Streetbeat News

Stock Prices

JAMF

Traders are monitoring Jamf Holding Corp. due to circulation of Zacks HomeRun Investor Newsletter which has picked the stock, potentially influencing its trading activity.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 3:34 pm

CVAC

GSK

CureVac N.V. (NASDAQ:CVAC) shares are rising after the company announced positive interim data from a Phase 2 study of its COVID-19 vaccine candidates developed with GSK Plc (NYSE:GSK). The study showed meaningful immune responses and favorable reactogenicity profiles at all tested doses. The vaccines use CureVac's second-generation mRNA technology and are part of a joint development program with GSK, which also includes a flu vaccine program.

Portfolio Pulse from Nabaparna Bhattacharya

January 05, 2024 | 3:31 pm

ROST

Ross Stores (NASDAQ:ROST) has delivered an average annual return of 12.02% over the past 20 years, outperforming the market by 4.61% annually. A $1000 investment in ROST 20 years ago would be worth $9,721.45 today. Ross Stores currently has a market cap of $45.98 billion. The article highlights the impact of compounded returns on investment growth over time.

Portfolio Pulse from Benzinga Insights

January 05, 2024 | 3:30 pm

ASML

Over the past 5 years, ASML Holding (NASDAQ:ASML) has produced an average annual return of 35.25%, outperforming the market by 22.41%. A $100 investment in ASML 5 years ago would be worth $449.27 today. ASML's market capitalization currently stands at $276.74 billion. The key takeaway is the significant impact of compounded returns on investment growth over time.

Portfolio Pulse from Benzinga Insights

January 05, 2024 | 3:30 pm

GOEV

Wedbush analyst Daniel Ives has initiated coverage on Canoo (NASDAQ:GOEV) with an Outperform rating and set a price target of $4 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 3:26 pm

AZN

GRCL

AstraZeneca (NASDAQ:AZN) is set to acquire Gracell Biotechnologies Inc. (NASDAQ:GRCL) for up to $1.2 billion, an 86% premium over its pre-announcement share price. The deal offers hope for cash-strapped Chinese biotechs, as Gracell's shares surged 60.3% post-announcement. Gracell, which focuses on CAR-T cell therapy for cancer treatment, has been operating at a loss with its most advanced product still in phase 1 trials. The acquisition by AstraZeneca will bolster its cell therapy capabilities, taking over Gracell's technology and trials. However, the sector faces uncertainty due to an FDA investigation into potential risks associated with CAR-T therapies.

Portfolio Pulse from The Bamboo Works

January 05, 2024 | 3:26 pm

HWKN

Hawkins Inc. (NASDAQ: HWKN) has seen increased institutional holdings, with firms like Charles Schwab Investment Management, Citadel Advisors, and Renaissance Technologies adding to their positions. Hawkins reported strong Q2 FY24 earnings with record gross profit and operating income, and growth in its Water Treatment segment. The company has a history of dividend growth and share repurchases, maintaining a low payout ratio. Management's compensation aligns with shareholder interests, and the company boasts high ROE and ROIC. Hawkins has solid financial health with low debt and is expected to grow due to capital expenditures. A reverse discounted cash flow analysis suggests that HWKN is undervalued, with a potential implied return of nearly 60%.

Portfolio Pulse from Quiver Quantitative

January 05, 2024 | 3:23 pm

YUMC

Yum China's stock (YUMC) is trading lower following a downgrade by JP Morgan from 'Overweight' to 'Neutral'.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 3:21 pm

AXGN

ELAN

GBX

KRUS

The Greenbrier Companies, Inc. (NYSE:GBX) reported strong earnings, surpassing estimates with adjusted EPS of 96 cents against expected 73 cents. FY24 revenue is projected between $3.4 billion to $3.7 billion, compared to estimates of $3.58 billion. Greenbrier's shares jumped 13.8% to $50.50. Other stocks also moved higher, including AxoGen, Kura Sushi USA, Peloton Interactive, and Elanco Animal Health, following positive financial updates, upgrades, and executive announcements.

Portfolio Pulse from Avi Kapoor

January 05, 2024 | 3:18 pm

TEAM

Oppenheimer has recommended buying Atlassian (TEAM) shares on the pullback, leading to an increase in the stock's trading price.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 3:16 pm